71 related articles for article (PubMed ID: 27325273)
1. Efficient Protocol for the Identification of Hypoxic Cell Radiosensitisers.
Hong CR; Wang J; Hicks KO; Hay MP
Adv Exp Med Biol; 2016; 899():269-90. PubMed ID: 27325273
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis and Anticancer Evaluation of Nitroimidazole Radiosensitisers.
Liew LP; Shome A; Wong WW; Hong CR; Hicks KO; Jamieson SMF; Hay MP
Molecules; 2023 May; 28(11):. PubMed ID: 37298933
[TBL] [Abstract][Full Text] [Related]
3. Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers.
Bonnet M; Hong CR; Gu Y; Anderson RF; Wilson WR; Pruijn FB; Wang J; Hicks KO; Hay MP
Bioorg Med Chem; 2014 Apr; 22(7):2123-32. PubMed ID: 24650701
[TBL] [Abstract][Full Text] [Related]
4. Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers.
Bischoff P; Altmeyer A; Dumont F
Expert Opin Ther Pat; 2009 May; 19(5):643-62. PubMed ID: 19441939
[TBL] [Abstract][Full Text] [Related]
5. Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides.
Bonnet M; Hong CR; Wong WW; Liew LP; Shome A; Wang J; Gu Y; Stevenson RJ; Qi W; Anderson RF; Pruijn FB; Wilson WR; Jamieson SMF; Hicks KO; Hay MP
J Med Chem; 2018 Feb; 61(3):1241-1254. PubMed ID: 29253343
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361.
Wong WW; Jackson RK; Liew LP; Dickson BD; Cheng GJ; Lipert B; Gu Y; Hunter FW; Wilson WR; Hay MP
Biochem Pharmacol; 2019 Nov; 169():113641. PubMed ID: 31541630
[TBL] [Abstract][Full Text] [Related]
7. Gold nanoparticle cellular uptake, toxicity and radiosensitisation in hypoxic conditions.
Jain S; Coulter JA; Butterworth KT; Hounsell AR; McMahon SJ; Hyland WB; Muir MF; Dickson GR; Prise KM; Currell FJ; Hirst DG; O'Sullivan JM
Radiother Oncol; 2014 Feb; 110(2):342-7. PubMed ID: 24444528
[TBL] [Abstract][Full Text] [Related]
8. Chemical radiosensitizers for use in radiotherapy.
Wardman P
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):397-417. PubMed ID: 17478086
[TBL] [Abstract][Full Text] [Related]
9. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Takahashi M; Abe M
Br J Cancer Suppl; 1996 Jul; 27():S61-4. PubMed ID: 8763848
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers.
Powell C; Mikropoulos C; Kaye SB; Nutting CM; Bhide SA; Newbold K; Harrington KJ
Cancer Treat Rev; 2010 Nov; 36(7):566-75. PubMed ID: 20409643
[TBL] [Abstract][Full Text] [Related]
11. Icotinib hydrochloride enhances the effect of radiotherapy by affecting DNA repair in colorectal cancer cells.
Ma H; Bi J; Liu T; Ke Y; Zhang S; Zhang T
Oncol Rep; 2015 Mar; 33(3):1161-70. PubMed ID: 25572529
[TBL] [Abstract][Full Text] [Related]
12. Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): radiosensitization efficiency and toxicity.
Oya N; Shibamoto Y; Sasai K; Shibata T; Murata R; Takagi T; Iwai H; Suzuki T; Abe M
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):119-27. PubMed ID: 7642409
[TBL] [Abstract][Full Text] [Related]
13. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
Hicks KO; Myint H; Patterson AV; Pruijn FB; Siim BG; Patel K; Wilson WR
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):560-71. PubMed ID: 17869669
[TBL] [Abstract][Full Text] [Related]
14. Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs.
Jackson RK; Liew LP; Hay MP
Clin Oncol (R Coll Radiol); 2019 May; 31(5):290-302. PubMed ID: 30853148
[TBL] [Abstract][Full Text] [Related]
15. [Hypoxic cell radiosensitizer present status and problems from viewpoint of clinical radiotherapy].
Ono K; Sasai K; Masunaga S; Kitakabu Y; Fushiki M; Kinashi Y; Takahashi M; Abe M
Gan No Rinsho; 1990 Oct; 36(13):2255-8. PubMed ID: 2250344
[TBL] [Abstract][Full Text] [Related]
16. Targeting tumour hypoxia to improve outcome of stereotactic radiotherapy.
Wittenborn TR; Horsman MR
Acta Oncol; 2015; 54(9):1385-92. PubMed ID: 26329662
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, transportability and hypoxiaselective binding of 1-beta-D-(5-Deoxy-5-fluororibofuranosyl)-2-nitroimidazole (beta-5-FAZR), a configurational isomer of the clinical hypoxia marker, FAZA.
Emami S; Kumar P; Yang J; Kresolic Z; Paproski R; Cass C; McEwan AJ; Wiebe LI
J Pharm Pharm Sci; 2007; 10(2):237-45. PubMed ID: 17706182
[TBL] [Abstract][Full Text] [Related]
18. Using YC-1 to overcome the radioresistance of hypoxic cancer cells.
Moon SY; Chang HW; Roh JL; Kim GC; Choi SH; Lee SW; Cho KJ; Nam SY; Kim SY
Oral Oncol; 2009 Oct; 45(10):915-9. PubMed ID: 19457706
[TBL] [Abstract][Full Text] [Related]
19. Effect of 1-methyl-5-sulfonamide-4-nitroimidazole and 1-methyl-5-bromide-4-nitroimidazole on the radiosensitivity of EMT6 tumor cells.
Rockwell S; Irvin CG; Nierenburg M
Cancer Treat Rep; 1986 Mar; 70(3):411-3. PubMed ID: 3955554
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-inducible factor pathway inhibition resolves tumor hypoxia and improves local tumor control after single-dose irradiation.
Helbig L; Koi L; Brüchner K; Gurtner K; Hess-Stumpp H; Unterschemmann K; Pruschy M; Baumann M; Yaromina A; Zips D
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):159-66. PubMed ID: 24331663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
